|
Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study). |
|
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - Roche Pharma AG |
Research Funding - Roche Pharma AG (Inst); Roche Pharma AG (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca (Inst) |
Patents, Royalties, Other Intellectual Property - University of Cologne |
|
|
Consulting or Advisory Role - AstraZeneca; Roche/Genentech |
Research Funding - AstraZeneca (Inst) |